MonoSol Rx signs agreement with Hikma for thin film products in the Middle East

MonoSol Rx has entered into an agreement for thin film pharmaceutical products with Hikma Pharmaceutical, a manufacturer of generic and in-licensed pharmaceutical products.

MonoSol Rx has entered into an agreement for thin film pharmaceutical products with Hikma Pharmaceutical, a manufacturer of generic and in-licensed pharmaceutical products.

MonoSol Rx is the developer of PharmFilm technology and a drug delivery company specialising in dissolving thin film pharmaceutical products.

Under terms of the agreement, Hikma will exclusively distribute in the Middle East three products based on PharmFilm technology. Hikma will obtain all registrations and approvals required to market the products throughout the region.

MonoSol Rx will receive milestone payments and payments for the purchase of product supply.

Mark Schobel, president and chief executive of MonoSol Rx, said: "In addition to expanding our reach into new geographic territories, our partnership with Hikma further validates our proprietary PharmFilm technology, leadership in thin film drug development, and growing intellectual property portfolio."

Companies